Active Biotech AB's directed new share issue fully subscribed


Active Biotech AB's directed share issue has been fully subscribed. The issue is generating approximately SEK 266 million in proceeds to Active Biotech. The number of Series B shares increased by 1,400,000, following the new issue.

In connection with the new issue, Bo Håkansson is selling 388,811 Series B shares to institutional investors, corresponding to the number of shares converted in his convertible debenture loan holding.

Following the issue and full conversion of the convertible loan, the number of shares in Active Biotech will amount to 11,246,293, of which 2,243,360 are Series A shares and 9,002,933 Series B shares.

Overall, the directed share issue and the new issue with pre-emptive rights for shareholders which has already been implemented have generated more than SEK 500 Million for Active Biotech.

Lund, 5 June 1998
Active Biotech AB (publ)

Bo Håkansson, Managing Director